Video

Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

Transcript

With the first 2 anticancer biosimilars having recently entered the market and more waiting to enter, do you think biosimilars will start to play a bigger role in oncology?

I think absolutely. They already have. What we’re seeing on the biosimilar front is actually a greater adoption than most folks thought initially for the non-supportive chemotherapy agents like Avastin, Herceptin, Rituxan. We were thinking maybe a 10% adoption right away. It’s looking more like it’s 15% to 20%. So, I think you’re going to see that trend continue. Biosimilars are going to be here to stay in my opinion and it’s going to be a great opportunity for community oncology.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Hira Ghani, DO, discusses underdiagnosed skin conditions in children
Nicole Bajic, MD
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Senator Vincent Polistina (R, New Jersey)
Amir Fathi, MD, Mass General
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo